Skip to main content

Table 3 Univariate and multivariate Cox proportional hazards regression analysis for DFS

From: Co-expression of SOX2 and HR-HPV RISH predicts poor prognosis in small cell neuroendocrine carcinoma of the uterine cervix

Variables Univariate Multivariate
HR (95% CI) P value HR (95% CI) P value
Age (years) (< 44 vs. ≥44) 1.241 (0.626–2.459) 0.536   
HPV DNA (pg/ml) (< 1 vs. ≥1) 0.659 (0.087–4.978) 0.686   
FIGO stage (≤IIA vs. ≥IIB) 1.797 (0.630–5.128) 0.273   
Pathological type (SCNEC -alone vs. SCNEC -mix) 1.455 (0.685–3.092) 0.330   
Pre-operative Chemotherapy (No vs. Yes) 0.841 (0.408–1.733) 0.638   
Post-operative Chemotherapy (No vs. Yes) 0.372 (0.113–1.224) 0.104   
Post-operative Radiotherapy (No vs. Yes) 0.790 (0.398–1.565) 0.499   
Tumor size (cm) (< 2 vs. 2–4 vs. ≥4) 1.132 (0.675–1.899) 0.637   
Stromal invasion (<  1/2 vs. ≥1/2) 1.382 (0.660–2.892) 0.391   
Endometrial invasion (No vs. Yes) 1.136 (0.347–3.722) 0.833   
Parametrium invasion (No vs. Yes) 2.359 (0.910–6.119) 0.077   
CIN (No vs. Yes) 1.171 (0.509–2.696) 0.711   
LNM (No vs. Yes) 1.071 (0.536–2.141) 0.845   
Nerve invasion (No vs. Yes) 2.707 (1.310–5.594) 0.007 3.398 (1.606–7.190) 0.001
LVI (No vs. Yes) 2.061 (0.928–4.576) 0.076   
N-marker (≤2+ vs. > 2+) 1.472 (0.449–4.828) 0.523   
MMR (pMMR vs. dMMR) 0.039 (0.001–2.416) 0.123   
Ki67 (< 60 vs. ≥60%) 3.244 (0.777–13.551) 0.107   
SOX2 (Low vs. High) 2.401 (1.044–5.524) 0.039 2.530 (1.092–5.863) 0.030
P16INK4A (− vs. +) 2.246 (0.685–7.366) 0.182   
HR-HPV RISH (− vs. +) 4.309 (1.019–19.208) 0.047 6.113 (1.406–26.581) 0.016
SOX2/ P16INK4A (AI vs. AII vs. AIII) 2.123 (1.108–4.067) 0.023 1.239 (0.564–2.721) 0.593
SOX2/ HR-HPV RISH (BI vs. BII vs. BIII) 3.220 (1.532–6.771) 0.002 2.880 (1.199–6.919) 0.018
  1. CIN Cervical Intraepithelial Neoplasia, LNM Lymph Node Metastasis, LVI Lymphatic Vessel Invasion, N-marker Neuroendocrine-marker, MMR Mismatch Repair, AI SOX2Low/P16INK4A-; AII: SOX2High/P16INK4A- or SOX2Low/P16INK4A+; AIII: SOX2High/P16INK4A+; BI: SOX2Low/HR-HPV RISH-; BII: SOX2High/HR-HPV RISH- or SOX2Low/HR-HPV RISH+; BIII: SOX2High/HR-HPV RISH+